Abatacept now available on NHS for rheumatoid arthritis

NICE has overturned its original decision to reject the rheumatoid arthritis treatment abatacept (Orencia).

Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.
Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.

In a review of its 2008 guidance, the institute has ruled that abatacept, in combination with methotrexate, can be considered for adults with severe active rheumatoid arthritis who are unresponsive or intolerant to a DMARD (including at least one TNF inhibitor) and in whom rituximab is unsuitable.

Adalimumab, etanercept and infliximab are recommended as other treatment options alongside abatacept.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...